TNFRSF10A and non-small cell lung carcinoma: Recombinant human TRAIL (rhTRAIL) or agonist monoclonal antibodies (mAbs) against DR4/DR5, collectively referred as to pro-apoptotic receptor agonists (PARAs), have been subjected to clinical trials for a variety of cancer cell types, including malignant melanoma and NSCLC cells.